Ascendis Pharma A (ASND) Cash from Financing Activities (2014 - 2026)

Ascendis Pharma A has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$43.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$43.1 million, down 127.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.1 million (down 90.61% YoY), and the FY2025 annual result was $64.3 million, down 86.45% from the prior year.
• Cash from Financing Activities came in at -$43.1 million for Q1 2026 at Ascendis Pharma A, down from $31.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $469.9 million in Q3 2024 to a low of -$43.1 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is $92967.8 (2024), against an average of $64.8 million.
• Across the five-year window, Cash from Financing Activities jumped 1850254.95% in 2022 and slumped 573.35% in 2023, its largest moves.
• Ascendis Pharma A's Cash from Financing Activities stood at $1.4 million in 2022, then plunged by 573.35% to -$6.5 million in 2023, then surged by 101.43% to $92967.8 in 2024, then surged by 34212.36% to $31.9 million in 2025, then sank by 235.18% to -$43.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$43.1 million (Q1 2026), $31.9 million (Q4 2025), and $45.4 million (Q3 2025), per Business Quant data.